BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1
57163 results:

  • 1. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
    Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
    Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
    Wang X; Yang Y
    Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021.
    Qin Y; Tang C; Li J; Gong J
    BMC Cancer; 2024 May; 24(1):594. PubMed ID: 38750424
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Non-specific uptake of
    Li Y; Gao J; Li Y; Duan X; Shen C
    Sci Rep; 2024 May; 14(1):11141. PubMed ID: 38750103
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
    Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
    Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Assessing quality of hepato-pancreato-biliary surgery: nationwide benchmarking.
    de Graaff MR; Hendriks TE; Wouters M; Nielen M; de Hingh I; Koerkamp BG; van Santvoort HC; Busch OR; den Dulk M; Klaase JM; van Zwet E; Bonsing BA; Grünhagen DJ; Besselink MG; Kok NFM
    Br J Surg; 2024 May; 111(5):. PubMed ID: 38747683
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
    Ooi SL; Micalos PS; Kim J; Pak SC
    Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinician-Level Knowledge and Barriers to Hepatocellular Carcinoma Surveillance.
    Wong RJ; Jones PD; Niu B; Therapondos G; Thamer M; Kshirsagar O; Zhang Y; Pinheiro P; Kyalwazi B; Fass R; Khalili M; Singal AG
    JAMA Netw Open; 2024 May; 7(5):e2411076. PubMed ID: 38743424
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Impact of changes in malignant tumor death spectrum on life expectancy in Tianjin residents from 1999-2019].
    Jiang TT; Wang SY; Yin XL; Xu JH; Wang DZ
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):461-470. PubMed ID: 38742360
    [No Abstract]    [Full Text] [Related]  

  • 14. [The influence of knocking down the expression of low-density lipoprotein receptor associated proteins on the vascular abnormalities in hepatocellular carcinoma and its mechanisms].
    Wu Q; Zhan LL; Wang Y; He YC; Chen L; Chen ZZ; Li GT; Liu DM; Bao X; Liu XM; Guo H; Song TQ
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):399-408. PubMed ID: 38742353
    [No Abstract]    [Full Text] [Related]  

  • 15. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
    Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
    Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
    Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
    Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The clinical significance of long non-coding RNAs MALAT1 and CASC2 in the diagnosis of HCV-related hepatocellular carcinoma.
    Golam RM; Khalil MAF; Shaker OG; Ahmed TI; Elguaad MKA; Hassan EA; El-Ansary MRM; Ismail A; Kandil YI; Mohammed OA; Doghish AS
    PLoS One; 2024; 19(5):e0303314. PubMed ID: 38739668
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
    Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
    JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
    Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
    Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
    Zhao J; Liu Z; Yang K; Shen S; Peng J
    Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2859.